Sugi Predict

Sugi Predict / Compounds / SCHEMBL3385822

SCHEMBL3385822

SCHEMBL3385822

O=C1CCCCC1COCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.48
▸ PSEN1 P49768 1/20 0.46
▸ PSEN2 P49810 1/20 0.46
▸ APH1B Q8WW43 1/20 0.46
▸ NCSTN Q92542 1/20 0.46
▸ APH1A Q96BI3 1/20 0.46
▸ PSENEN Q9NZ42 1/20 0.46
▸ LMNA P02545 1/20 0.44
▸ TSHR P16473 1/20 0.42
▸ MT-CO2 P00403 1/20 0.41
▸ ALOX5 P09917 1/20 0.41
▸ MCL1 Q07820 1/20 0.41
▸ CTSL P07711 1/20 0.40
▸ CTSB P07858 1/20 0.40
▸ CTSK P43235 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ RAB9A P51151 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8619425 0.95 PSEN1 (0.50) KDM4EPSEN1PSEN2APH1BNCSTN
SCHEMBL3814418 0.89 TSHR (0.52) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL1969569 0.89 TSHR (0.52) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL6979320 0.84 KDM4E (0.51) KDM4EPSEN1PSEN2APH1BNCSTN
SCHEMBL16372157 0.81 CTSL (0.43) LMNATSHRCTSLCTSBCTSK
SCHEMBL9956815 0.81 TSHR (0.42) LMNATSHRCTSLCTSBCTSK
SCHEMBL5722136 0.80 KDM4E (0.41) KDM4EALDH1A1
SCHEMBL29169546 0.78 PTGS2 (0.57) KDM4EMT-CO2ALOX5MCL1MAPT
SCHEMBL9790769 0.78 PTGS2 (0.57) KDM4EMT-CO2ALOX5MCL1MAPT
SCHEMBL4595 0.78 PTGS2 (0.57) KDM4EMT-CO2ALOX5MCL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-20 — — US disclosed
EP-4100004-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2022-12-14 — — EP disclosed
WO-2021158634-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-08-12 — — WO disclosed
CN-105601485-B A kind of preparation method of voglibose intermediate 重庆植恩药业有限公司 2017-11-07 — — CN disclosed
CN-105254514-B A kind of preparation method of Tetrabenzyl voglibose 重庆植恩药业有限公司 2017-09-05 — — CN disclosed
EP-2655370-B1 COMPOSITIONS AND METHODS FOR MODULATING FXR NOVARTIS AG (CH) 2017-08-02 — — EP disclosed
US-20150366856-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NOVARTIS AG (CH) 2015-12-24 — — US disclosed
US-20150366856-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NOVARTIS AG (CH) 2015-12-24 — — US disclosed
US-20150366856-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NOVARTIS AG (CH) 2015-12-24 — — US disclosed
US-9150568-B2 Compositions and methods for modulating FXR NOVARTIS AG (CH) 2015-10-06 — — US disclosed
WO-2012087519-A1 COMPOSITIONS AND METHODS FOR MODULATING FXR IRM LLC (BM) 2012-06-28 — — WO disclosed
EP-1914232-B1 N-DIHYDROXYALKYL-SUBSTITUTED 2-OXOIMIDAZOLE DERIVATIVES BANYU PHARMA CO LTD (JP) 2010-12-15 — — EP disclosed
US-20080103178-A1 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives MSD K.K. (JP) 2008-05-01 — — US disclosed
EP-1914232-A1 N-DIHYDROXYALKYL-SUBSTITUTED 2-OXOIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2008-04-23 — — EP disclosed
US-7300947-B2 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-11-27 — — US disclosed
US-20070015792-A1 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives MSD K.K. (JP) 2007-01-18 — — US disclosed
US-5276053-A Dibenzothiopyranylamines WARNER-LAMBERT COMPANY (US) 1994-01-04 — — US disclosed
US-5180736-A Treatment and prevention of brain disorders WARNER-LAMBERT COMPANY (US) 1993-01-19 — — US disclosed
US-5071853-A Amine-substituted hexahydroindeno(2,1-b)pyrroles, -indeno(2,1-c)pyridines or -indeno(2,1-d)azepines; cerebral ischemia or infarction WARNER-LAMBERT COMPANY 1991-12-10 — — US disclosed
EP-0388977-A2 Polycyclic amines useful as cerebrovascular agents WARNER-LAMBERT COMPANY (US) 1990-09-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070015792-A1 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives OPRL1, OPRK1, GPR119 KDM4E 3930/4885PSEN1 1497/4885PSEN2 765/4885
US-20150366856-A1 COMPOUNDS AND METHODS FOR MODULATING FXR NR1H4, SLC10A1, FXR1 KDM4E 3613/4885PSEN1 4604/4885PSEN2 4634/4885
US-20230122219-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KDM4E 190/4885PSEN1 2925/4885PSEN2 2858/4885
US-20080103178-A1 N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives OPRL1, OPRK1, GPR119 KDM4E 3930/4885PSEN1 1497/4885PSEN2 765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.